1.47 (-%)
As of Nov 20, 2024
Source:
We are a clinical-stage biopharmaceutical company focused on developing advanced therapies for autoimmune and inflammatory diseases, specifically through the inhibition of the complement and leukotriene pathways. Each of these systems has scientifically well-supported causative roles in the diseases we are targeting. We believe that blocking early mediators of inflammation will prevent initiation and continual amplification of the processes that cause certain diseases.
Country | United States |
Headquarters | new york, new york |
Phone Number | (646) 350-0702 |
Industry | manufacturing |
CEO | Rachelle Jacques |
Website | akaritx.com |